1. Case Report: The First Case of COVID-19 in Bhutan.
- Author
-
LeVine S, Dhakal GP, Penjor T, Chuki P, Namgyal K, Tshokey, and Watts M
- Subjects
- Aged, Anti-Bacterial Agents therapeutic use, Antiviral Agents therapeutic use, Betacoronavirus drug effects, Bhutan, COVID-19, Contact Tracing, Coronavirus Infections drug therapy, Coronavirus Infections immunology, Coronavirus Infections pathology, Humans, Hyperlipidemias drug therapy, Hyperlipidemias immunology, Hyperlipidemias pathology, Hypertension drug therapy, Hypertension immunology, Hypertension pathology, Immunocompromised Host, Immunoglobulins, Intravenous therapeutic use, Lung drug effects, Lung pathology, Lung virology, Male, Pandemics, Pneumonia, Viral drug therapy, Pneumonia, Viral immunology, Pneumonia, Viral pathology, SARS-CoV-2, Tomography, X-Ray Computed, Travel, Treatment Outcome, Ultrasonography, United States, Betacoronavirus pathogenicity, Coronavirus Infections diagnostic imaging, Hyperlipidemias diagnostic imaging, Hypertension diagnostic imaging, Lung diagnostic imaging, Pneumonia, Viral diagnostic imaging
- Abstract
The initial cases of novel coronavirus disease-19 (COVID-19) in a country are of utmost importance given their impact on healthcare providers, the country's preparedness response, and the initial molding of the public perception toward this pandemic. In Bhutan, the index case was a 76-year-old immunocompromised man who had traveled from the United States and entered Bhutan as a tourist. He presented initially with vague gastrointerestinal symptoms and later a cough. His atypical presentation led to a delay in diagnosis, but ultimately he was isolated and tested. On confirming the diagnosis of COVID-19, the patient was isolated in a separate hospital with a dedicated medical care team. All contacts were traced and quarantined. The patient's respiratory status deteriorated despite broad-spectrum antivirals, antibiotics, and intensive supportive care. He required intubation and was given a trial of intravenous immunoglobulin to modulate his likely aberrant immune response. Subsequently, the patient's clinical status improved, and after 8 days of hospitalization, he was transferred out of the country, where he recovered. This was a learning experience for the treating medical staff, the government, and the people of Bhutan.
- Published
- 2020
- Full Text
- View/download PDF